Question: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Constraint: The Compound can be represented with the SMILES C#Cc1cnc2nc(O)n(C(CC)CC)c2n1.
Result: Phase 3 Clinical Trials
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
C#Cc1cnc2nc(O)n(C(CC)CC)c2n1
C#Cc1cnc2nc(O)n(C(CC)CC)c2n1
5-ethynyl-3-pentan-3-ylimidazo[4,5-b]pyrazin-2-ol
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.